2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow ACT-389949: new trials by email Literature Review of ACT-389949 trials Research Report on ACT-389949
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects ACT-389949 40 mg, ACT-389949 200 mg, ACT-389949 800 mg - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 65 | 2012-11-01 | 2018-07-10 |
| Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 ACT-389949 1 mg, ACT-389949 5 mg, ACT-389949 20 mg - Healthy Subjects | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 65 | 2011-11-01 | 2018-07-10 |
Idorsia Pharmaceuticals Ltd. (2)
Netherlands (1) · United Kingdom (1)
Alison Mackie, MSc (1) · Hans Cruz, PhD (1)